| Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity NCT03574597 | Completed | P3 | Novo Nordisk A/S |
| A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight NCT05567796 | Active, not recruiting | P3 | Novo Nordisk A/S |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Recruiting | P3 | Novo Nordisk A/S |
| STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity NCT03548935 | Completed | P3 | Novo Nordisk A/S |
| A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) NCT05646706 | Completed | P3 | Novo Nordisk A/S |
| Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity NCT03552757 | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes | Recruiting | P3 | Kailera |
| A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight NCT05394519 | Completed | P3 | Novo Nordisk A/S |
| GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward NCT06977438 | Not yet recruiting | P4 | University of Minnesota |
| A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation | Active, not recruiting | P2 | Regeneron Pharmaceuticals |
| AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Not yet recruiting | P3 | Novo Nordisk A/S |
| Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus NCT02453711 | Completed | P2 | Novo Nordisk A/S |
| Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity NCT03548987 | Completed | P3 | Novo Nordisk A/S |
| Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity NCT05579977 | Terminated | P2 | Pfizer |
| A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight NCT06131437 | Completed | P3 | Novo Nordisk A/S |
| A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities NCT05822830 | Completed | P3 | Eli Lilly and Company |
| Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) NCT05035095 | Completed | P3 | Novo Nordisk A/S |
| A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide | Not yet recruiting | P3 | Novo Nordisk A/S |
| A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo NCT06131372 | Completed | P2 | Novo Nordisk A/S |
| Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program NCT03611582 | Completed | P3 | Novo Nordisk A/S |
| A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | Active, not recruiting | P3 | Novo Nordisk A/S |
| A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) NCT05514535 | Completed | P3 | Novo Nordisk A/S |
| A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | Active, not recruiting | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. |
| Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity NCT04788511 | Completed | P3 | Novo Nordisk A/S |
| A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight NCT05649137 | Completed | P3 | Novo Nordisk A/S |
| Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese NCT05616013 | Completed | P2 | Eli Lilly and Company |
| A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America NCT05579249 | Completed | P4 | Novo Nordisk A/S |
| STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss | Active, not recruiting | P4 | Novo Nordisk A/S |
| Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus NCT06616961 | Not yet recruiting | P3 | Popular Medical College Hospital |
| A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） | Active, not recruiting | P3 | Innovent Biologics (Suzhou) Co. Ltd. |
| Semaglutide in Treatment of Obesity NCT06604624 | Completed | P3 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight NCT07253285 | Recruiting | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients NCT07036172 | Recruiting | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight | Recruiting | P3 | Novo Nordisk A/S |
| Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects | Recruiting | P3 | Gan & Lee Pharmaceuticals. |
| A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects NCT06738979 | Not yet recruiting | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis NCT05064735 | Completed | P3 | Novo Nordisk A/S |
| STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity NCT03811574 | Completed | P3 | Novo Nordisk A/S |
| A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity | Active, not recruiting | P3 | Novo Nordisk A/S |
| A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) NCT06584916 | Completed | P3 | Eli Lilly and Company |
| Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity. NCT04251156 | Completed | P3 | Novo Nordisk A/S |
| A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy® NCT06633783 | Not yet recruiting | P3 | Hangzhou Jiuyuan Gene Engineering Co. Ltd., |
| BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity | Not yet recruiting | P3 | Carnot Laboratories |
| A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity NCT06184568 | Completed | P3 | Innovent Biologics (Suzhou) Co. Ltd. |
| Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity NCT04074161 | Completed | P3 | Novo Nordisk A/S |
| A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight NCT05813925 | Completed | P3 | Novo Nordisk A/S |
| Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range NCT05564117 | Completed | P3 | Novo Nordisk A/S |
| Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity NCT03693430 | Completed | P3 | Novo Nordisk A/S |
| A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight NCT05996848 | Completed | P3 | Novo Nordisk A/S |
| A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight NCT06388187 | Completed | P3 | Novo Nordisk A/S |
| A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | Not yet recruiting | P3 | Novo Nordisk A/S |
| DUTCH Weight Control in Atrial Fibrillation Study NCT06184633 | Recruiting | P4 | Rijnstate Hospital |
| A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | Recruiting | P3 | Vanda Pharmaceuticals |
| Semaglutide for Low Back Pain NCT07731256 | Not yet recruiting | P2 | Washington University School of Medicine |
| Young Adults With Early-onset Obesity Treated With Semaglutide NCT05574439 | Completed | P4 | Signe Torekov |
| A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range NCT06041217 | Completed | P3 | Novo Nordisk A/S |
| Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss | Not yet recruiting | P4 | Alain Dagher |
| A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity | Recruiting | P2 | Novo Nordisk A/S |
| A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial) NCT06605703 | Completed | P4 | WW International Inc |
| PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults NCT06863363 | Not yet recruiting | P4 | Shanghai Zhongshan Hospital |